298 related articles for article (PubMed ID: 19382170)
21. Effect of riluzole (Rilutek) treatment on plasma amino acid percentages in amyotrophic lateral sclerosis patients.
Iłzecka J; Stelmasiak Z; Solski J; Wawrzycki S; Szpetnar M
Neurol Sci; 2003 Nov; 24(4):290-2. PubMed ID: 14658053
[TBL] [Abstract][Full Text] [Related]
22. Improving efficiency of ALS clinical trials using lead-in designs.
Moore DH; Miller RG
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():57-60. PubMed ID: 15512875
[TBL] [Abstract][Full Text] [Related]
23. Optimizing the ongoing search for new treatments for Parkinson disease: using futility designs.
Tilley BC; Palesch YY; Kieburtz K; Ravina B; Huang P; Elm JJ; Shannon K; Wooten GF; Tanner CM; Goetz GC;
Neurology; 2006 Mar; 66(5):628-33. PubMed ID: 16534099
[TBL] [Abstract][Full Text] [Related]
24. What are the implications of early diagnosis? Maintaining optimal health as long as possible.
Brooks BR
Neurology; 1999; 53(8 Suppl 5):S43-5; discussion S55-7. PubMed ID: 10560637
[TBL] [Abstract][Full Text] [Related]
25. Blood pressure elevations in riluzole-treated patients with amyotrophic lateral sclerosis.
Scelsa SN; Khan I
Eur Neurol; 2000; 43(4):224-7. PubMed ID: 10828653
[TBL] [Abstract][Full Text] [Related]
26. Neuroprotective agents for clinical trials in ALS: a systematic assessment.
Traynor BJ; Bruijn L; Conwit R; Beal F; O'Neill G; Fagan SC; Cudkowicz ME
Neurology; 2006 Jul; 67(1):20-7. PubMed ID: 16832072
[TBL] [Abstract][Full Text] [Related]
27. Novel designs and end points for phase II clinical trials.
Adjei AA; Christian M; Ivy P
Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic trials in ALS.
Bradley W
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Apr; 4(1):6-7. PubMed ID: 12745610
[No Abstract] [Full Text] [Related]
29. Clinical trials in ALS: what did we learn from recent trials in humans?
Meininger V
Neurodegener Dis; 2005; 2(3-4):208-14. PubMed ID: 16909027
[TBL] [Abstract][Full Text] [Related]
30. An efficient multi-stage, single-arm Phase II futility design for ALS.
Palesch YY; Tilley BC
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Sep; 5 Suppl 1():55-6. PubMed ID: 15512874
[No Abstract] [Full Text] [Related]
31. Historical control monotherapy design in the treatment of epilepsy.
French JA; Wang S; Warnock B; Temkin N
Epilepsia; 2010 Oct; 51(10):1936-43. PubMed ID: 20561024
[TBL] [Abstract][Full Text] [Related]
32. The biopharmaceutical industry and new drugs for amyotrophic lateral sclerosis.
Malta E
Adv Neurol; 1995; 68():263-9; discussion 271-5. PubMed ID: 8787239
[TBL] [Abstract][Full Text] [Related]
33. Designing clinical trials in amyotrophic lateral sclerosis.
Shefner JM
Phys Med Rehabil Clin N Am; 2008 Aug; 19(3):495-508, ix. PubMed ID: 18625412
[TBL] [Abstract][Full Text] [Related]
34. Sequential designs for clinical trials in amyotrophic lateral sclerosis.
Groeneveld GJ; van der Tweel I; Wokke JH; van den Berg LH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2004 Dec; 5(4):202-7. PubMed ID: 15799547
[TBL] [Abstract][Full Text] [Related]
35. What has changed with riluzole?
Meininger V; Lacomblez L; Salachas F
J Neurol; 2000 Dec; 247 Suppl 6():VI/19-22. PubMed ID: 19714404
[TBL] [Abstract][Full Text] [Related]
36. Phase II clinical trials in oncology: strengths and limitations of two-stage designs.
Schlesselman JJ; Reis IM
Cancer Invest; 2006; 24(4):404-12. PubMed ID: 16777694
[TBL] [Abstract][Full Text] [Related]
37. Intravenous thyrotropin-releasing hormone in patients with amyotrophic lateral sclerosis. Dose-response and randomized concurrent placebo-controlled pilot studies.
Brooks BR; Sufit RL; Montgomery GK; Beaulieu DA; Erickson LM
Neurol Clin; 1987 Feb; 5(1):143-58. PubMed ID: 3104750
[TBL] [Abstract][Full Text] [Related]
38. Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis: the effect of riluzole treatment.
Andreadou E; Kapaki E; Kokotis P; Paraskevas GP; Katsaros N; Libitaki G; Zis V; Sfagos C; Vassilopoulos D
Clin Neurol Neurosurg; 2008 Mar; 110(3):222-6. PubMed ID: 18055102
[TBL] [Abstract][Full Text] [Related]
39. The rationale for placebo-controlled trials: methodology and policy considerations.
Miller FG
Am J Bioeth; 2009 Sep; 9(9):49-50. PubMed ID: 19998193
[No Abstract] [Full Text] [Related]
40. [Tolerance of riluzole in a phase IIIb clinical trial].
Lacomblez L; Dib M; Doppler V; Faudet A; Robin V; Salachas F; Bensimon G; Meininger V
Therapie; 2002; 57(1):65-71. PubMed ID: 12090150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
